What Happened to HLB Innovation?
HLB Innovation announced a 99.4% drop in operating profit, from KRW 2,205 million to KRW 13 million, in its revised semi-annual report released on August 14, 2025. The decline is primarily attributed to deteriorating profitability in its core semiconductor component business.
Behind the Earnings Shock
The semiconductor industry downturn and intensified competition led to decreased sales volume and increased cost burdens, despite a rise in lead frame selling prices. Furthermore, increased R&D expenses from investments in the bio business (Verismo Therapeutics) contributed to the profit decline.
HLB Innovation’s Future Outlook
A conservative investment approach is necessary in the short term. Investors should closely monitor the recovery of profitability in the semiconductor business and the progress of clinical trials in the bio business. In the long term, focus on the potential of the bio business and the company’s efforts to restructure its business portfolio. The success of Verismo Therapeutics’ CAR-T therapy development will be a critical factor.
Action Plan for Investors
- Short-term Strategy: Identify signs of earnings improvement and monitor financial soundness.
- Long-term Strategy: Evaluate the bio business potential and observe business portfolio restructuring.
Continuous attention should also be paid to financial health indicators, including bond maturity, interest payment ability, and debt ratio trends.